Case reportEfficacy of thalidomide in systemic onset juvenile rheumatoid arthritis
Introduction
Systemic onset juvenile idiopathic arthritis (SoJIA) is a severe, debilitating inflammatory condition characterized by fever, rash and arthritis with many laboratory abnormalities including leukocytosis, thromobocytosis, anaemia, dramatically elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), and elevated ferritin with a specific pattern of cytokine abnormalities [1]. The current definition of Juvenile idiopathic arthritis (JIA) is arthritis of unknown aetiology that begins before the 16th birthday and persists for at least 6 weeks [2]. It has recently been suggested that SoJIA is a distinct entity from JIA, and that the aetiology, pathogenesis, and therapy of children with SoJIA should be considered separately from those with other forms of JIA [3]. Approximately one-third of children with SoJIA are dependent on corticosteroids to control the systemic manifestations of the disease and are at high-risk for steroid-associated morbidity. The permanent physiologic and psychological sequelae associated with long-term steroid use are well documented and should be avoided [1], [4]. Current non-steroidal therapies available for the treatment of SoJIA alone or in combination include: anakina, autologous stem cell transplantation, azathioprine, cyclophosphamide, cyclosporine, etanercept, infliximab, intravenous gamma-globulin, methotrexate, sulfasalazine, and tocilizumab [3]. None has proven to be consistently successful. Thalidomide is a unique anti-inflammatory agent that reduces the production of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) and suppresses angiogenesis and cell adhesion molecule expression [5], [6].
Section snippets
Patient 1
A 9-year-old girl who fulfilled the criteria for SoJIA was seen in our center. She was started on prednisone 0.2 mg/kg/day, methotrexate 10 mg/m2/week p.o. and non-steroidal anti-inflammatory drugs (NSAID) (aspirin 80 mg/kg/day). The dose of methotrexate was raised to 15 mg/m2/week but marked active synovitis and constitutional symptoms persisted. It was decided to initiate etanercept at a dose of 0.4 mg/kg SC twice weekly due to the inadequate therapeutic response to conventional treatment. Before
Discussion
It is known that, in children with active SoJIA, TNF-α is significantly overproduced while interferon gamma levels are markedly decreased [8], [9]. Polymorphisms in the 5′-flanking promoter/enhancer region of TNF-α in patients with SoJIA have been reported compared with other types of JIA and healthy controls [10]. Levels of interleukin-6, interleukin-8 and monocyte chemo-attractant protein-1 are also altered. Interleukin-6 levels increase in SoJIA patients with active disease and decrease with
Acknowledgment
The authors thank David Buss for his editorial assistance.
References (18)
- et al.
Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis
J Pediatr
(2002) - et al.
Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multi center study
J Pediatr
(2004) When should we use TNF antagonists in children with rheumatic disease?
Joint Bone Spine
(2007)- et al.
Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years
J Rheumatol
(2000) - et al.
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis
J Rheumatol
(2001) - et al.
Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis
Curr Opin Rheumatol
(2005) - et al.
Special considerations in the use of glucocorticoids in children
Pediatr Rev
(1995) - et al.
Immunological effects of thalidomide and its chemical and functional analogs
Crit Rev Immunol
(2002) - et al.
Thalidomide: dermatological indications, mechanisms of action and side-effects
Br J Dermatol
(2005)
Cited by (34)
Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting
2022, European Journal of PharmacologyCitation Excerpt :Thalidomide also plays a vital role in the modulation of various pro-inflammatory cytokines (Rowland et al., 1998; Franks et al., 2004), especially TNF-α (Wnendt et al., 1996). Indeed, later studies revealed that thalidomide exerts anti-inflammatory effects in various inflammatory diseases (García-Carrasco et al., 2007; Rodrigues et al., 2007), including GI inflammation (Bariol et al., 2002; Mazzon et al., 2005; Prakash et al., 2008). To summarize, the anti-inflammatory effects of antiemetic drugs in the GI tract is critical in preventing CINV, emphasizing the pathogenic role of GI inflammation in CINV.
Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders
2020, Pharmacology and TherapeuticsCitation Excerpt :Studies have shown that thalidomide is potentially effective in relieving joint pain in RA patients (Gutierrez-Rodriguez, Starusta-Bacal, & Gutierrez-Montes, 1989), demonstrating a refractoriness phenotype partially mediated by TNF-α (Dredge, Marriott, & Dalgleish, 2002; J. J. Wu, Huang, Pang, Hsu, & Tyring, 2005). In a case study, thalidomide has been shown to successfully ameliorate inflammatory conditions in patients with juvenile RA, probably by reducing the production of IL-6 (Garcia-Carrasco, Fuentes-Alexandro, Escarcega, Rojas-Rodriguez, & Escobar, 2007). In a transgenic model of PD overexpressing α-syn under the murine Thy-1 promoter, thalidomide restored striatal dopamine fibre loss and reduced the production of IL-1β, IL-6, IFN-γ and TNF-α (Martinez & Peplow, 2018).
Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches
2015, Clinical ImmunologyCitation Excerpt :The mechanism of action, however, remained elusive and published evidence for the use of thalidomide in sJIA is sparse and limited to case reports and small series. Given the general lack of controlled studies and the availability of modern target-directed treatment options, the use of this agent appears obsolete and cannot generally be recommended [66]. As a very last resort in desperate situations, autologous hematopoietic stem-cell transplantation may be considered.
Review of thalidomide use in the pediatric population
2015, Journal of the American Academy of DermatologySystemic Juvenile Idiopathic Arthritis
2015, Textbook of Pediatric RheumatologyPharmacology and Drug Therapy: Nonbiologic Therapies
2015, Textbook of Pediatric Rheumatology